Phase 3Data readout

Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept)

Wet age-related macular degeneration , Age-related macular degeneration, Eye disease

ADVMAdverum Biotechnologies Inc.

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept)
Development stage: Phase 3
Event type: Data readout
Indication: Wet age-related macular degeneration , Age-related macular degeneration, Eye disease

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept) in Wet age-related macular degeneration , Age-related macular degeneration, Eye disease . The expected timing is based on the latest available company guidance and may change.

Development notes

LUNA, OPTIC, ARTEMIS, AQUARIUS trials. 3/3/25- ARTEMIS trial initiated. 5/14/25- Initiate AQUARIUS trial in H2 2025. 8/12/25- LUNA follow-up data in Q4 2025. 9/22/25- ARTEMIS enrollment completion in Q4 2025; topline data H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source